MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13075-017-1439-1

Медицинская библиотека · Arthritis research & therapy · 2017

Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.

Deyab Gia, Hokstad Ingrid, Whist Jon Elling, Smastuen Milada Cvancarova, Agewall Stefan, Lyberg Torstein, Ronda Nicoletta, Mikkelsen Knut, Hjeltnes Gunnbjorg, Hollan Ivana

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), leads to increased cardiovascular disease occurrence probably due to atherosclerosis. One of the first stages in atherogenesis is endothelial dysfunction (ED). Therefore, we aimed to compare endothelial function (EF) in patients with IA, and to examine the effects of methotrexate (MTX) monotherapy and antitumor necrosis factor (anti-TNF) treatment with or without MTX comedication (anti-TNF ± MTX) on EF.

METHODS

From the PSARA observational study, all patients with RA (n = 64), PsA (n = 29), and AS (n = 20) were evaluated for EF. In patients with ED at baseline (n = 40), we evaluated changes in the Reactive Hyperemic Index (RHI) after 6 weeks and 6 months of antirheumatic therapy.

RESULTS

In IA patients with ED, RHI significantly improved after 6 weeks (p < 0.001) and 6 months (p < 0.001) of treatment, independent of changes in disease activity parameters. After 6 months, RHI had improved more in the MTX group than in the anti-TNF ± MTX group, and the difference remained statistically significant after adjustments for potential confounders. Among patients with active RA, AS, and PsA, those with AS appeared to have the worst endothelial function, although they were the youngest.

CONCLUSION

Treatment with MTX and anti-TNF ± MTX was associated with a relatively fast improvement of EF in IA patients with ED, independent of change in disease activity. Therefore, modes of action other than the anti-inflammatory effect may contribute to the EF improvement. After 6 months, the EF improvement was more pronounced in the MTX group than in the anti-TNF ± MTX group.

TRIAL REGISTRATION: Clinicaltrials, NCT00902005 . Registered on 13 May 2009.

Для цитирования: Deyab Gia, Hokstad Ingrid, Whist Jon Elling, Smastuen Milada Cvancarova, Agewall Stefan, Lyberg Torstein, Ronda Nicoletta, Mikkelsen Knut, Hjeltnes Gunnbjorg, Hollan Ivana. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.. Arthritis research & therapy. 2017. DOI: 10.1186/s13075-017-1439-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.